Live Science on MSNOpinion
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
CRISPR Therapeutics › Investing in modestly sized growth stocks can lead to significant returns, but oftentimes it requires taking on a fair bit of risk and being willing to wait at least a few years ...
A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback